Impact of Diabetes on Cardiovascular Risk C.Richard Conti M.D. MACC Oct 16,2004 GWICC Beijing, PRC.

Slides:



Advertisements
Similar presentations
Diabetes Overview Managing Diabetes in Primary Care.
Advertisements

TIME TO ACT Type 2 diabetes, the metabolic syndrome and cardiovascular disease in Europe CONTENTS Section One: Background to type 2 diabetes, the metabolic.
Ronald A. Codario, MD Assistant Clinical Professor of Medicine
BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.
Susan Alexander, DNP, CNS, CRNP, BC- ADM College of Nursing University of Alabama in Huntsville Clinical Affiliation: Outpatient Diabetes Self-Management.
1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Diabetes Mellitus Type 2
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
TM © 1999 Professional Postgraduate Services ® Diabetes and Cardiovascular Disease Epidemiology Clinical Trials Management Nathan Wong.
The concept of Diabetes & CV risk: A lifetime risk challenge
Type 2 diabetes and high blood pressure How explosive is the cocktail?
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Diabetes – A 21 st Century Epidemic Diagnosis and what is it A common disease An expensive disease A serious disease A treatable disease A preventable.
השמנת יתר חמד " ע פרופ ' ארדון רובינשטין.
Metabolic Syndrome, Diabetes, and Cardiovascular Disease: Implications for Preventive Cardiology Nathan D. Wong, PhD, FACC, FAHA Professor and Director.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
How To Be Healthy Without Killing Yourself B Bottenberg, D.O., FNLA, FACOI.
Blood glucose: is lower better for diabetic patients?
Epidemiology of Diabetes Mellitus by Santi Martini Departemen of Epidemiology Faculty of Public Health University of Airlangga.
SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos.
Cardiovascular Disease in Women Module I: Epidemiology.
The Science: CHD and Diabetes as Co-morbidities Kathy Reims, MD Center for Strategic Innovation 8/27/07.
Hypertension the Community - Overview HYPERTENSION IN THE COMMUNITY: OVERVIEW.
Obesity, Metabolic Syndrome and Diabetes in Hispanics: implications on Cardiovascular Disease 2011 Eduardo de Marchena M.D., F.A.C.C., F.A.C.P. Professor.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
Modern Management of Cholesterol in the High-Risk Patient.
Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.
FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.
Risk of Type 2 Diabetes and It’s Complications Along The Continuum of Fasting Plasma Glucose Gregory A. Nichols, PhD Collaborative Diabetes Education Conference.
Diabetes National Diabetes Control Programme
VBWG Insulin Resistance and Cardiovascular Disease: New Perspectives From Vascular Biology.
Consider testing if person is: – Overweight or obese with additional risk factor for diabetes – Age 45 or older Obtain: A1C or FPG or 2-hour plasma glucose.
Hyperglycemia and Acute Coronary Syndromes. Cardiovascular disease and diabetes Bell DSH. Diabetes Care. 2003;26: Centers for Disease Control.
Glycemic Control: When the Lower is Not the “Better”?
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.
Prevention of Diabetes Mellitus Prof. Adel El-Etriby Professor of Cardiology Ain Shams Faculty of Medicine.
Diabetes mellitus “ Basic approach” Dr Sajith.V.S MBBS,MD (Gen Med )
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP
Dr. I. Selvaraj Indian Railways Medical Service B.Sc., M.B.B.S., M.D.,D.P.H., D.I.H., PGCHFW ( NIHFW,New Delhi)., Life member of Indian Association of.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
2007 Hypertension as a Public Health Risk January, 2007.
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
Measures of Hyperglycemia Random plasma glucose (RPG)—without regard to time of last meal Fasting plasma glucose (FPG)—before breakfast Oral glucose tolerance.
Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial
Abstract The metabolic syndrome (MetS) has surpassed smoking as the number one cause of cardiovascular deaths in the US. However, it remains under diagnosed.
Dr John Cox Diabetes in Primary Care Conference Cork
Clinical Outcomes with Newer Antihyperglycemic Agents
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Insulin Delivery Systems Atlanta Diabetes Associates
Macrovascular Complications Microvascular Complications
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Type 2 diabetes: Overlap of clinical conditions
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials  Sanjay Rajagopalan  Journal of Indian College.
Level of risk factor control in the overall sample and by gender
Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus  James H. O'Keefe, MD, Mohammad Abuannadi,
Diabetes – A 21st Century Epidemic
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
Presentation transcript:

Impact of Diabetes on Cardiovascular Risk C.Richard Conti M.D. MACC Oct 16,2004 GWICC Beijing, PRC

Image (Prevention/Vascular) Overlap of Four Common Conditions 25 KB File Type: GIF Source ACCEL image provided by the American College of Cardiology Foundation

Diabetes and Cardiovascular Risk An Association between diabetes mellitus and angina pectoris was first described in 1883, shortly after it was hypothesized that angina pectoris was due to atherosclerosis Vergely P. De l’angine de poitrine dans ses rapports avec le diabete. Gaz hedb de ned (ser 2) 1883;20:364

Clinical Trial (INVEST) Blood Pressure Control

NCEP (ATP III) Definition of Metabolic Syndrome 3 of these 5 factors have to be present: –Increased waist circumference (>102 cm in men or >88 cm in women) –Hypertriglyceridemia (>150 mg/dl) –Low HDL-cholesterol (<40 mg/ml in men and 50 mg/ml in women) –Hypertension (BP >130/80 mm Hg) –Fasting serum glucose >110 mg/dl (Validated with the WOSCOPS data)

Image Abnormalities Associated With the Metabolic Syndrome 114 KB File Type: JPG Source ACCEL image provided by the American College of Cardiology Foundation

IGT Insulin resistance Increased insulin resistance Fasting glucose Hyperglycemia Insulin secretion Hyperinsulinemia, then b-cell failure Adapted from International Diabetes Center (IDC), Minneapolis, Minnesota Insulin Resistance and  -Cell Dysfunction Are Fundamental to Type 2 Diabetes Post- prandial glucose Abnormal glucose tolerance NormalType 2 Diabetes

50% of Type 2 Diabetes Patients Have Complications at the Time of Diagnosis Retinopathy, glaucoma or cataracts Nephropathy Neuropathy MICROVASCULAR MACROVASCULAR Cerebrovascular disease Coronary heart disease Peripheral vascular disease UK Prospective Diabetes Study Group. UKPDS 33. Lancet 1998; 352: 837–853

Microalbuminuria in Metabolic Syndrome (MS) Patients Microalbuminuria mg/24h p = ANOVA Segura et al JASN, 2004

Ryden L, et al. Lancet 2002; Glucose and CV Risk (Oral Glucose Tolerance Test) All patients had experienced an MI; n = 300 At Hospital Discharge 12 Months Later Type 2 diabetics24%36% Impaired glucose tolerance 41%32% Normal glucose tolerance 35%32%

Age and gender adjusted CHD, CVD and total mortality in US adults with metabolic syndrome with and without diabetes and pre existing CVD. n=6255 Follow up 133 patient years. Malik et al Circ 2004;110:

Prevalence of the Metabolic Syndrome Among U.S. Adults Unadjusted prevalence21.8% Age-adjusted prevalence23.7% –Prevalence increased with age –Mexican Americans had the highest prevalence (31.9%) Ford ES, et al. JAMA 2002; 287: 356–9

Seven-year incidence in a Finnish-based cohort *P < vs no prior MI † P < vs no diabetes Adapted from Haffner SM. New Engl J Med 1998; 339: 229–234 Risk of Myocardial Infarction Is Increased in Type 2 Diabetes 0% 20% 40% Risk of Fatal or Non-Fatal Myocardial Infarction No prior myocardial infarction Prior myocardial infarction Non-Diabetic SubjectsType 2 Diabetic Subjects * n = 1,304 * † † 60%

Causes of Mortality in Diabetic Patients Panzram G. Diabetologia 1987; 30: 123–31 % Deaths in Diabetic Patients Not Specified Others Tuberculosis Accident/Suicide Gangrene Renal Insufficiency Diabetic Coma Infections Tumours Stroke Myocardial Infarction

Predicted Growth in the Prevalence of Diabetes WHO. The World Health Report, AfricaAmericasEastern Med EuropeSoutheast Asia Western Pacific Year Estimated Prevalence In Millions

Coronary Event Rates for Diabetic and Nondiabetic Participants Woscops